MERS-CoV spike protein: Targets for vaccines and therapeutics.
about
Risk factors for MERS coronavirus infection in dromedary camels in Burkina Faso, Ethiopia, and Morocco, 2015MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC.Evaluation of a Real-Time Reverse Transcription-PCR (RT-PCR) Assay for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Clinical Samples from an Outbreak in South Korea in 2015.A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
P2860
MERS-CoV spike protein: Targets for vaccines and therapeutics.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@ast
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@en
type
label
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@ast
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@en
prefLabel
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@ast
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@en
P2093
P1433
P1476
MERS-CoV spike protein: Targets for vaccines and therapeutics.
@en
P2093
George F Gao
Guangwen Lu
Jinghua Yan
P304
P356
10.1016/J.ANTIVIRAL.2016.07.015
P50
P577
2016-07-25T00:00:00Z